Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 18/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 7/20 | 0.49 |
| ▸ | PLA2G10 | O15496 | 4/20 | 0.49 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.49 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.46 |
| ▸ | PLA2G2F | Q9BZM2 | 2/20 | 0.44 |
| ▸ | PLA2G2D | Q9UNK4 | 2/20 | 0.44 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.44 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.44 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.44 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.44 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862586 | 1.00 | PLA2G2A (0.50) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL7968359 | 0.90 | PLA2G2A (0.45) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL7965916 | 0.90 | PLA2G2A (0.48) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL7962981 | 0.88 | PLA2G2A (0.45) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL7963319 | 0.88 | PLA2G2A (0.42) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL817716 | 0.87 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL29862858 | 0.87 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL7969267 | 0.86 | PLA2G2A (0.43) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL7472322 | 0.85 | PLA2G2A (0.59) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL7963427 | 0.85 | PLA2G2A (0.42) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | claimed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | claimed |
| JP-2004503586-A | — | — | 2004-02-05 | — | — | JP | claimed |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | claimed |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | claimed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | claimed |
| US-6514984-B1 | Human non-pancreatic secretory phospholipase A2 inhibitors | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | claimed |
| WO-2002005796-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | claimed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| EP-3448378-B1 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | OPHIREX INC (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | CONCORD (HK) INTERNATIONAL EDUCATION LIMITED (HK) | 2003-05-08 | — | — | US | disclosed |
| US-6514984-B1 | Human non-pancreatic secretory phospholipase A2 inhibitors | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | disclosed |
| WO-2001055108-A2 | USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | ELI LILLY AND COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | PLA2G2A 24/4885PLA2G1B 9/4885PLA2G10 10/4885 |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | PLA2G2A 11/4885PLA2G1B 13/4885PLA2G10 10/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | PLA2G2A 4/4885PLA2G1B 6/4885PLA2G10 11/4885 |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | IDO2, SPINT2, IDO1 | PLA2G2A 63/4885PLA2G1B 26/4885PLA2G10 221/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | PLA2G2A 19/4885PLA2G1B 3/4885PLA2G10 9/4885 |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | SERPINB1, ELANE, SPINT2 | PLA2G2A 127/4885PLA2G1B 74/4885PLA2G10 97/4885 |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | TPP2, PLAAT2, PLAA | PLA2G2A 139/4885PLA2G1B 59/4885PLA2G10 43/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | PLA2G2A 12/4885PLA2G1B 11/4885PLA2G10 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.